| Outcome | Probability | Yes Bid | Yes Ask | 24h Change | Volume | |
|---|---|---|---|---|---|---|
| Any psychedelic substance for medical use | 0% | 0¢ | 0¢ | — | $0 | Trade → |
This market asks whether the U.S. Food and Drug Administration will grant at least one formal approval for a psychedelic substance for a medical indication at any time before 2027. The outcome matters because an FDA approval changes clinical access, reimbursement possibilities, and commercial incentives for therapies built on those substances.
Clinical research into substances commonly described as psychedelics (for example, psilocybin and MDMA) has accelerated over the past decade, with several programs reaching late-stage clinical trials and some regulatory precedents for related compounds already established. The FDA evaluates safety, efficacy, and manufacturing quality through formal pathways (e.g., NDA/BLA) and can use expedited programs that shorten review timelines for promising therapies.
Market prices reflect collective expectations about whether an FDA approval will be announced before the start of 2027 and update as trial results, regulatory filings, and agency actions are reported. They are not clinical endorsements but a real-time summary of available information and trader beliefs.
This event refers to a formal FDA approval for a psychedelic substance to be marketed for a medical indication, typically via an approved New Drug Application (NDA) or Biologics License Application (BLA) for a specified indication. State-level scheduling changes, decriminalization, Emergency Use Authorizations, or research-only approvals do not qualify unless they include an FDA marketing approval.
Yes, an FDA approval for a marketed product that contains a psychedelic substance or its defined therapeutic derivative counts, provided the approval is for a medical indication and is granted by the FDA as a marketing authorization.
Substances commonly discussed in late-stage clinical programs include psilocybin and MDMA; regulatory attention also extends to ketamine-related treatments and other serotonergic or entactogenic compounds in development. The event applies to any psychedelic substance that receives FDA marketing approval within the timeframe.
Designations like breakthrough therapy, fast track, or priority review can shorten review times and increase agency engagement, making approvals on a shorter timeline more feasible if supporting evidence is strong. However, expedited status does not guarantee approval—robust efficacy and safety data are still required.
Key items include Phase 3 trial primary endpoint results, sponsor submissions of NDAs/BLAs, FDA filing acceptance letters, advisory committee meeting announcements and votes, major safety signals, and official FDA approval notices. Manufacturing or labeling issues and complete response letters from the FDA are also market-moving.